Page last updated: 2024-08-16

propafenone and diclofenac

propafenone has been researched along with diclofenac in 38 studies

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (21.05)29.6817
2010's17 (44.74)24.3611
2020's13 (34.21)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM1
Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W1
Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U1
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ1
Bellman, K; Knegtel, RM; Settimo, L1
Colabufo, NA; Khlebnikov, AI; Kirpotina, LN; Lacivita, E; Leopoldo, M; Perrone, R; Quinn, MT; Schepetkin, IA; Stama, ML1
Bennis, K; Ducki, S; Lesage, F; Vivier, D1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Abou-Taleb, N; Amblard, F; Amiralaei, S; Bassit, L; Coats, SJ; Domaoal, RA; Ehteshami, M; Khalil, A; Liu, P; Mahmoud, S; McBrayer, T; Ollinger Russell, O; Sari, O; Schinazi, RF; Schutter, C; Tao, S; Whitaker, T; Zhou, L; Zhou, S1
Bertagnin, C; Desta, S; Ding, X; Fang, Z; Gao, P; Huang, B; Jia, H; Jia, R; Ju, H; Kang, D; Kong, X; Liang, X; Liu, X; Loregian, A; Lu, H; Lu, X; Ma, X; Murugan, NA; Poongavanam, V; Sun, L; Tian, Y; Xu, W; Zhan, P; Zhang, J1
Sun, J; Tong, D; Yang, D; Zhang, D; Zhang, F; Zhao, G1
Chen, B; Hu, Y; Lei, Z; Liu, K; Meng, P; Tian, Y; Wang, B; Wang, K; Yang, F1
Bertagnin, C; Ding, X; Fang, Z; Gao, P; Huang, B; Jia, H; Jia, R; Kang, D; Kong, X; Liu, X; Loregian, A; Ma, X; Murugan, NA; Poongavanam, V; Sun, Z; Tian, Y; Xu, W; Zhan, P; Zhang, J1
Amblard, F; Bassit, LC; Cho, JH; Coats, SJ; De Schutter, C; Domaoal, RA; Ehteshami, M; Jiang, Y; Kasthuri, M; Lee, S; Lin, BY; McBrayer, T; Mengshetti, S; Ollinger Russell, O; Ovadia, R; Pascual, ML; Pattassery, J; Sari, O; Schinazi, RF; Tao, S; Uher, L; Verma, K; Whitaker, T; Zhang, H; Zhou, L1
Liu, M; Liu, Y; Ran, F; Zhang, D; Zhao, G1
Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W1
Fang, F; Li, J; Lv, X; Ma, X; Qiao, T; Shen, L; Tao, Q; Zhong, G1
Cao, R; Chen, B; Lei, Z; Liu, K; Tian, Y; Wang, K; Yang, F; Zhang, K; Zhao, H; Zhao, L; Zhu, H1
Hu, LL; Lin, XH; Liu, M; Liu, WJ; Lu, W; Tang, SW; Wang, PL; Wang, W; Wang, X; Yang, JJ; Yu, WW; Zhang, HK; Zhang, Q1
Chen, CH; Cocklin, S; Dick, A; Ding, X; Gao, P; Huang, T; Lee, KH; Liu, X; Meuser, ME; Sun, L; Zalloum, WA; Zhan, P1
Chen, B; Lei, Z; Liu, K; Tian, Y; Wang, J; Wang, K; Yang, F; Zhang, H; Zhang, K; Zhao, H; Zhao, X; Zhu, H1
Chen, C; Gao, Z; Gong, P; Han, Y; Hou, Y; Huang, D; Li, L; Li, S; Li, Y; Qin, M; Sun, Y; Tian, Y; Xu, S; Zhao, Y1
Chai, X; Chen, S; Jiang, BE; Jiang, X; Liang, Q; Liu, M; Lu, W; Qiu, ZL; Sun, XB; Yang, JJ; Yi, C; Yu, LF; Zhang, HK; Zhang, Q1
Hu, B; Hu, Y; Jiang, S; Meng, P; Tian, Y; Wang, J; Wang, K; Ye, Z; Zhang, H; Zhao, H; Zhu, H1
Daelemans, D; De Clercq, E; Gao, P; Ginex, T; Huang, B; Jiang, X; Kang, D; Liu, X; Luque, FJ; Pannecouque, C; Zhan, P; Zhang, J1
Cherukupalli, S; Cocklin, S; De Clercq, E; Dick, A; Ding, X; Huang, T; Jiang, X; Kang, D; Liu, X; Meuser, ME; Pannecouque, C; Sun, L; Tao, Y; Xu, S; Zalloum, WA; Zhan, P; Zhang, X1
Cherukupalli, S; Cocklin, S; De Clercq, E; Dick, A; Ding, D; Ding, X; Gao, S; Huang, T; Jiang, X; Kang, D; Liu, X; Meuser, ME; Pannecouque, C; Sun, L; Tao, Y; Xu, S; Zalloum, WA; Zhan, P; Zhang, X1
An, R; Cao, C; Feng, YL; Guo, C; Guo, MB; Hou, Z; Wang, X; Wang, YX; Zhang, R; Zhao, XY1
Bertagnin, C; Du, R; Guizzo, L; Hou, L; Huang, B; Jia, R; Ju, H; Kang, D; Kong, X; Li, P; Liu, X; Loregian, A; Ma, X; Murugan, NA; Poongavanam, V; Zhan, P; Zhang, Y1
Fu, Y; Gong, Q; Huang, J; Huang, Y; Li, J; Li, X; Mao, F; Wang, H; Xu, Y; You, H; Zhang, D; Zhang, H; Zhu, J1

Reviews

2 review(s) available for propafenone and diclofenac

ArticleYear
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
    Journal of medicinal chemistry, 2016, 06-09, Volume: 59, Issue:11

    Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship

2016
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

36 other study(ies) available for propafenone and diclofenac

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
    Journal of medicinal chemistry, 2004, Mar-25, Volume: 47, Issue:7

    Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
    Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship

2008
Determination of log D via automated microfluidic liquid-liquid extraction.
    Journal of medicinal chemistry, 2008, Aug-28, Volume: 51, Issue:16

    Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution

2009
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:1

    Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests

2012
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Journal of applied toxicology : JAT, 2012, Volume: 32, Issue:10

    Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:1

    Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
    Bioorganic & medicinal chemistry, 2015, Jul-15, Volume: 23, Issue:14

    Topics: Amides; Animals; Calcium; Chemistry Techniques, Synthetic; Drug Evaluation, Preclinical; Drug Stability; HL-60 Cells; Humans; Mice, Inbred BALB C; Microsomes, Liver; Neutrophil Activation; Rats; Receptors, Formyl Peptide; Receptors, Lipoxin; Species Specificity; Stereoisomerism

2015
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
    Journal of medicinal chemistry, 2017, 07-13, Volume: 60, Issue:13

    Topics: Antiviral Agents; Cells, Cultured; Dose-Response Relationship, Drug; Genotype; Hep G2 Cells; Hepacivirus; Humans; Microbial Sensitivity Tests; Molecular Structure; Prodrugs; Ribonucleotides; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication

2017
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
    Journal of medicinal chemistry, 2018, Jul-26, Volume: 61, Issue:14

    Topics: Cell Line; Drug Design; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Male; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Safety; Viral Proteins

2018
Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant.
    MedChemComm, 2018, Aug-01, Volume: 9, Issue:8

    Topics:

2018
Design, synthesis, and evaluation of carboxyl-modified oseltamivir derivatives with improved lipophilicity as neuraminidase inhibitors.
    Bioorganic & medicinal chemistry letters, 2018, 11-15, Volume: 28, Issue:21

    Topics: Antiviral Agents; Catalytic Domain; Drug Design; Drug Stability; Enzyme Inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Influenza A Virus, H5N1 Subtype; Microsomes, Liver; Molecular Docking Simulation; Neuraminidase; Oseltamivir

2018
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
    Journal of medicinal chemistry, 2018, 11-21, Volume: 61, Issue:22

    Topics: Animals; Antiviral Agents; Catalytic Domain; Dogs; Drug Design; Drug Resistance, Viral; Drug Stability; Humans; Influenza A virus; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Mutation; Neuraminidase; Nitrogen; Oseltamivir; Rats; Tissue Distribution

2018
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
    Journal of medicinal chemistry, 2019, 02-28, Volume: 62, Issue:4

    Topics: Animals; Antiviral Agents; Cell Line, Tumor; Deoxyribonucleosides; Deoxyuracil Nucleotides; Dogs; Drug Discovery; Enzyme Inhibitors; Hepacivirus; Humans; Male; Microsomes, Liver; Prodrugs; Viral Nonstructural Proteins

2019
Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
    Bioorganic & medicinal chemistry letters, 2019, 05-01, Volume: 29, Issue:9

    Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Proliferation; Drug Design; Half-Life; Humans; Lymphoma, Mantle-Cell; Microsomes, Liver; Pyrazoles; Structure-Activity Relationship

2019
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
    Journal of medicinal chemistry, 2019, 04-11, Volume: 62, Issue:7

    Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells

2019
Conformationally restricted quinazolone derivatives as PI3Kδ-selective inhibitors: the design, synthesis and biological evaluation.
    MedChemComm, 2019, Mar-01, Volume: 10, Issue:3

    Topics:

2019
Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
    European journal of medicinal chemistry, 2020, Jan-01, Volume: 185

    Topics: Animals; Antiviral Agents; Dogs; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Molecular Structure; Neuraminidase; Oseltamivir; Structure-Activity Relationship

2020
Discovery and Characterization of 1
    Journal of medicinal chemistry, 2020, 01-23, Volume: 63, Issue:2

    Topics: Animals; Calcium; Cell Line, Tumor; Colonic Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Drug Discovery; Female; HEK293 Cells; Humans; Immunotherapy; Macrophages; Mice; Mice, Inbred BALB C; Microsomes, Liver; Neoplasms; RAW 264.7 Cells; Receptors, Prostaglandin E, EP4 Subtype; Structure-Activity Relationship; T-Lymphocytes, Cytotoxic; Triazoles; Tumor Microenvironment

2020
Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.
    European journal of medicinal chemistry, 2020, Mar-15, Volume: 190

    Topics: Anti-HIV Agents; Capsid Proteins; Cell Line, Tumor; Drug Design; HIV-1; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Dynamics Simulation; Molecular Structure; Phenylalanine; Protein Binding; Structure-Activity Relationship; Triazoles; Virus Replication

2020
Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
    European journal of medicinal chemistry, 2020, Aug-15, Volume: 200

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Microbial Sensitivity Tests; Molecular Structure; Neuraminidase; Oseltamivir; Structure-Activity Relationship; Viral Proteins

2020
Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects.
    European journal of medicinal chemistry, 2021, Feb-15, Volume: 212

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzothiazoles; Carrageenan; Cell Survival; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Epoxide Hydrolases; Hep G2 Cells; Humans; Inflammation; Ligands; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship

2021
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
    Journal of medicinal chemistry, 2021, 01-14, Volume: 64, Issue:1

    Topics: Designer Drugs; Drug Discovery; Humans; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Structure-Activity Relationship

2021
Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.
    European journal of medicinal chemistry, 2021, Oct-05, Volume: 221

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Humans; Hydrazines; Influenza A virus; Microbial Sensitivity Tests; Molecular Structure; Mutation; Neuraminidase; Oseltamivir; Structure-Activity Relationship; Viral Proteins

2021
Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
    Journal of medicinal chemistry, 2021, 09-23, Volume: 64, Issue:18

    Topics: Anti-HIV Agents; Cell Line; Drug Design; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microsomes, Liver; Molecular Dynamics Simulation; Molecular Structure; Mutation; Protein Binding; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2021
Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors.
    European journal of medicinal chemistry, 2021, Dec-15, Volume: 226

    Topics: Anti-HIV Agents; Capsid Proteins; Dimerization; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Dynamics Simulation; Molecular Structure; Phenylalanine; Structure-Activity Relationship; Surface Plasmon Resonance

2021
Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability.
    European journal of medicinal chemistry, 2022, Jan-05, Volume: 227

    Topics: Anti-HIV Agents; Benzothiazoles; Capsid Proteins; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Phenylalanine; Structure-Activity Relationship; Virus Replication

2022
Discovery of novel aminosaccharide-based sulfonamide derivatives as potential carbonic anhydrase II inhibitors.
    Bioorganic & medicinal chemistry letters, 2021, 12-01, Volume: 53

    Topics: Amines; Animals; Carbohydrates; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Humans; Isoenzymes; Mice; Microsomes, Liver; Molecular Structure; Structure-Activity Relationship; Sulfonamides

2021
Identification of C5-NH
    Journal of medicinal chemistry, 2021, 12-23, Volume: 64, Issue:24

    Topics: Animals; Antiviral Agents; Biological Availability; Chick Embryo; Computer Simulation; Half-Life; Influenza A Virus, H5N1 Subtype; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship

2021
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Cholinesterase Inhibitors; Depression; Donepezil; Drug Design; Half-Life; Humans; Ligands; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Vilazodone Hydrochloride

2022